Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance

Histology and Histopathology

Volumn 20, Issue 4, 2005, Pages 1037-1044

  Surowiak, Pawel ^a,b,c   Matkowski, R ^a   Materna, V ^b   Gyorffy B ^b,d   Wojnar, A ^c   Pudelko, M ^c   Dziegiel, P ^a   Kornafel, J ^a   Zabel, M ^a,e  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Wroclaw   (Poland)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Breast cancer; Metallothionein; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; METALLOTHIONEIN; MONOCLONAL ANTIBODY; PARAFFIN; PROGESTERONE RECEPTOR; RECEPTOR ANTIBODY; STEROID RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DEATH; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTION; PROTEIN EXPRESSION; SURVIVAL TIME;

AGE FACTORS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; METALLOTHIONEIN; MIDDLE AGED; TAMOXIFEN;

EID: 27144482128     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dziegiel P., Forgacz J., Suder E., Surowiak P., Kornafel J. and Zabel M. (2003). Prognostic significance of metallothionein expression in correlation with Ki67 expression in adenocarcionmas of large intestine. Histol. Histopathol. 18, 401-407.
2. EBCTCG (1998). Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351, 1451-1462.
3. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., Ruby S.G., O'Malley F., Simpson J.F., Connoly J.L., Hayes D.F., Edge S.B., Lichter A. and Schnitt S.J. (2000). Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124, 966-978.
4. Fresno M., Wu W., Rodrigues J.M. and Nadji M. (1993). Localization of metallothionein in breast carcinomas. An imunohistochemical study. Virchows Arch. (A) 423, 215-219.
5. Friedline JA, Garret S,H,, Somji S,, Todd J.H and Sens D.A. (1998) Differential expression of the MT-1E gene in estrogen-receptor-positive and -negative human breast cancer cell lines. Am. J. Pathol. 152, 23-27.
6. Goulding H., Jasani B. and Pereteira H. (1995). Metallothionein expression in human breast cancer. Br. J. Cancer 72, 968-972.
7. Haerslev T., Jacobsen G.K. and Zadeler K. (1995). The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas. APMIS 103, 279-285.
8. Hamer D.H. (1986). Metallothionein. Annu. Rev. Biochem. 55, 913-951.
9. Harris H., Henderson R.A., Bhat R.A. and Komm B.S. (2001). Regulation of metallothionein II messenger ribonucleic acid measures exogenous estrogen receptor beta activity in SAOS-2 and LNCaPLN3 cells. Endocrinology 142, 645-652.
10. Hishikawa Y., Koji T., Dhar D.K., Kinugasa S., Yamaguchi M. and Nagasue N. (1999). Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br. J. Cancer 81, 712-720.
11. Ioachim E,, Kamina S,, Demou A,, Kontostolis M,, Lolis D. and Agnantis N.J. (1999). Immunohistochemical localistaion of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, p53, Rb, c-erbB-2, EGFR, steroid content and proliferation. Anticancer Res, 19, 2133-2139.
12. Ioachim E., Tsanou E., Briasoulis E., Batsis Ch., Karavailis V., Charchanti A., Pavlidis N. and Agnatis N.J. (2003). Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 12, 111-119.
13. Jin R., Bay B.H., Chow V.T., Tan P.H. and Lin V.C. (2000). Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast. Br. J. Cancer 83, 319-323.
14. Jin R,, Bay B.H. and Chow V.T.K. (2001a). Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res. Treat, 66, 265-272.
15. Jin R., Bay B-H., Chow V.T.K., Tan P-H. and Dheen T (2001b). Significance of metallothionein expression in breast myoepithelial cells. Cell Tissue Res. 303, 221-226.
16. Jin R., Chow V.T. and Tan P.H. (2002). Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 23, 81-86.
17. Kagi J.H.R. (1991) Overview of metallothionein. Methods Enzymol. 205, 613-626.
18. Ogawa Y., Moriya T., Kato Y., Oguma M., Ikeda K., Takashima T., Nakata B., Ishikawa T. and Hirakawa K. (2004). Immunohistochemical assesment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer, 11, 267-275.
19. Oyama T., Take H., Hikkino T., Iino Y. and Nakajima T. (1996). Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology 53, 112-117.
20. Plouffe L. jr (2000). Selective estrogen receptor modulators (SERMs) in clinical practice. J. Soc. Gynaecol. Invest. 7, S38-S52.
21. Remmele W. and Stegner H.E. (1987). Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8, 138-140.
22. Surowiak P., Dziegiel P., Zabel M., Matkowski R. and Kornafel J. (2001). Prognostic value of immunocytochemical estimation of estrogen receptor (ER) and of pS2 estrogen-dependent protein in cells of mammary ductal carcinoma. Analysis of five-year course of the disease. Folia Histochem. Cytobiol. 39, 143-144.
23. Surowiak P., Paluchowski P., Wysocka T., Wojnar A. and Zabel M. (2004). Steroid receptor status, proliferation and metallothionein expression in primary invasive ductal breast cancers. Pathol. Oncol. Res. 10, 207-211.
24. Tai S.K., Tan O.J. and Chow V.T. (2003). Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. Am. J. Pathol. 163, 2009-2019.
25. Theocharis S.E, Margeli A.P,, Klijanienko J.T. and Kouraklis G.P. (2004). Metallothionein expression in human neoplasia. Histopathology 43, 103-118.
26. Vazquez-Ramirez F.J, Gonzalez-Campora J.J., Hevia-Alvarez E., Fernandez-Santos J.M., Rios-Martin J.J., Otal-Salaverri C. and Gonzales-Campora R. (2000). P-glycoprotein, metallothionein and NM23 protein expressions in breast carcinoma. Pathol. Res. Pract. 196, 553-559.
27. Zhang R., Zhang H., Wei H. and Luo X. (2000). Expression of metallothionein in invasive ductal breast cancer and relation to prognosis. J. Environ. Pathol. Toxicol. Oncol. 19, 95-97.